Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Dana-Farber Cancer Institute
Modality
antibody_drug_conjugate
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05016947CT.gov Venetoclax Plus Inotuzumab for B-ALL | — | Active Not Recruiting | — | — | — |
NCT01535989CT.gov Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma | — | Completed | — | — | — |
NCT01055496CT.gov Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT00867087CT.gov Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT00724971CT.gov Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab | — | Completed | — | — | — |
NCT00717925CT.gov Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL) | — | Completed | — | — | — |
NCT00299494CT.gov Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) | — | Completed | — | — | — |
NCT00073749CT.gov Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Cell Non-Hodgkin Lymphoma
+42 more in the B-Cell Non-Hodgkin Lymphoma cohort
Other indications for Inotuzumab Ozogamicin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | — | P4 | BB · 69 |
| B-Cell Acute Lymphoblastic Leukemia | — | P4 | BB · 67 |
| Central Nervous System Leukemia | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- VindesineChildren's Cancer Group, ChinaBBB
- Anti-Cd20/Cd3 Monoclonal Antibody Regn1979University of BirminghamBBB
- CytarabineChildren's Cancer Group, ChinaBBB
- ZanubrutinibThe First Affiliated Hospital of Soochow UniversityBBB
- CamustineFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyBBB
Citation
Floatz Terminal. Inotuzumab Ozogamicin in B-Cell Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/inotuzumab-ozogamicin-b-cell-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →